Patents by Inventor Nigel J. Liverton

Nigel J. Liverton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridazines having cytokine inhibitory activity
    Patent number: 6602872
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Charles J. McIntyre, Nigel J. Liverton, David A. Claremon
  • N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
    Publication number: 20030119811
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: April 2, 2002
    Publication date: June 26, 2003
    Inventors: Nigel J. Liverton, John W. Butcher, Charles McIntyre, Christopher F. Claiborne, David A. Claremon, John A. McCauley, Joseph J. Romano, Wayne Thompson, Peter M. Munson
  • Compounds having cytokine inhibitory activity
    Patent number: 6492516
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: December 10, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, David A. Claremon, Cory R. Theberge
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Publication number: 20020165241
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: February 20, 2002
    Publication date: November 7, 2002
    Inventors: Christopher F. Claiborne, John W. Butcher, David A. Claremon, Brian E. Libby, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson, John A. McCauley
  • Iminopyrimidine NMDA NR2B receptor antagonists
    Patent number: 6440976
    Abstract: Compounds described by the chemical structural formula or a pharmaceutically acceptable salt thereof, are useful in the treatment of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in the treatment of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: August 27, 2002
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, John A. McCauley, Nigel J. Liverton, Cory R. Theberge
  • Substituted pyridones having cytokine inhibitory activity
    Patent number: 6403596
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, David A. Claremon, John W. Butcher, Cory R. Theberge
  • Cyclic amidines useful as NMDA NR2B antagonists
    Patent number: 6376530
    Abstract: The invention encompasses novel compounds of Formula I as well as a method of treating NMDA mediated diseases comprising administration to a patient in need of such treatment a non-toxic amount of a compound of Formula I effective to block the NMDA NR2B receptor sub-unit. The invention also encompasses certain pharmaceutical compositions for the treatment of NMDA mediated diseases comprising compounds of Formula I and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Radioligand and binding assay
    Publication number: 20020034730
    Abstract: The present invention is directed to the radioligand compound, [35S]-radiolabeled (+)-N-[1′-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydoxyspiro[2H-1-benzopyran-2,4′-piperidin]-6-yl]methanesulfonamide. Also within the scope of this invention is a method for identifying compounds that bind to the IKr channel, and may have antiarrhythmic activity.
    Type: Application
    Filed: July 12, 2001
    Publication date: March 21, 2002
    Inventors: John W. Butcher, David A. Claremon, Thomas M. Connolly, Jerzy Karczewski, Kenneth S. Koblan, Matthew J. Kostura, Nigel J. Liverton, Dennis C. Dean, David G. Melillo
  • Substituted imidazoles having cytokine inhibitory activity
    Publication number: 20020026056
    Abstract: There are disclosed compounds of formula (I) 1
    Type: Application
    Filed: December 20, 2000
    Publication date: February 28, 2002
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Iminopyrimidine NMDA NR2B receptor antagonists
    Publication number: 20020013329
    Abstract: Compounds described by the chemical structural formula 1
    Type: Application
    Filed: June 25, 2001
    Publication date: January 31, 2002
    Inventors: David A. Claremon, John A. McCauley, Nigel J. Liverton, Cory R. Theberge
  • Aryl amidines, compositions containing such compounds and methods of use
    Patent number: 6319944
    Abstract: Compounds represented by formula I: or a pharmaceutically acceptable salt or hydrate thereof, are disclosed. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: November 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, Brian Libby, Neil R. Curtis, Janusz Kulagowski
  • 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
    Patent number: 6316474
    Abstract: Benzimidazoles, substituted in the 2-position by substituted benzyl groups or heteroaryl groups are effective as NMDA NR2B antagonists and are useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: John A. McCauley, Cory R. Theberge, Nigel J. Liverton, David A. Claremon, Christopher F. Claiborne
  • Compounds having cytokine inhibitory activity
    Patent number: 6291457
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, David A. Claremon, Nigel J. Liverton, Kevin T. Nguyen
  • Benzodiazepine derivatives as antiarrhythmic agents
    Patent number: 6214823
    Abstract: This invention is concerned with novel compounds represented by structural formula I which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, John W. Butcher, David A. Claremon, Harold G. Selnick
  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 6207687
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which may be useful for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: March 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Substituted imidazoles having anti-cancer and cytokine inhibitory activity
    Patent number: 6083949
    Abstract: Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom.A pharmaceutical composition is also included.Methods of treating cancer and cytokine mediated diseases are also included.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: July 4, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, Christopher F. Claiborne, David A. Claremon, Harold G. Selnick
  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 5859041
    Abstract: Compounds represented by formula I: ##STR1## are disclosed. .sup.AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: January 12, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, David A. Claremon, John W. Butcher, Mark T. Bilodeau
  • 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
    Patent number: 5837719
    Abstract: The present invention addresses 2, 5-substituted aryl pyrroles of the formula: ##STR1## or a pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods of treatment. The compounds are useful for treating Cytokine mediated diseases, which refers to diseases or conditions in which excessive or unregulated production or activity of one or more cytokines occurs. Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor (TNF) are cytokines which are involved in immunoregulation and other physiological conditions, such as inflammation. The compounds also have glucagon antagonist activity.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: November 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Nigel J. Liverton, Gerald S. Ponticello, Harold G. Selnick, Nathan B. Mantlo
  • 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
    Patent number: 5792778
    Abstract: The present invention addresses 2-substituted aryl pyrroles, as well as compositions containing such compounds and methods of treatment. Cytokine mediated diseases refers to diseases or conditions in which excessive or unregulated production or activity of one or more cytokines occurs. Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor (TNF) are cytokines which are involved.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: August 11, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Nigel J. Liverton, Gerald S. Ponticello, Harold G. Selnick, Nathan B. Mantlo
  • Substituted imidazoles having anti-cancer and cytokine inhibitory activity
    Patent number: 5717100
    Abstract: Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 6 membered non-aromatic heterocycle containing only one N atom.A pharmaceutical composition is also included.Methods of treating cancer and cytokine mediated diseases are also included.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: February 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, David A. Claremon, Nigel J. Liverton